More patient deaths associated with intragastric balloon weight-loss systems | ACP Gastroenterology Monthly
Clinicians should closely monitor patients with intragastric balloons for complications and explain symptoms that could be signs of serious or life-threatening problems, the FDA advised.
In a letter to clinicians, the FDA noted five reports of unanticipated deaths that occurred from 2016 to the present in patients treated with liquid-filled intragastric balloon systems.
Recent studies assessed the safety and efficacy of bariatric surgery and a medication to treat obesity, while the U.S. Preventive Services Task Force updated its 2012 recommendations on behavioral interventions for adults with obesity.
A randomized, double-blind, placebo-controlled pilot trial compared the effects of liraglutide and placebo on gastric motor function, satiation, satiety, and weight in obese patients over a 16-week period.
This month's quiz asks readers to evaluate a patient with heartburn that awakens him at night and is not completely relieved by over-the-counter antacids.
ACP Gastroenterology Monthly delivers a monthly summary of news in gastroenterology and hepatology, including the latest research, clinical guidelines, and FDA drug actions.
Gastric bypass benefits persist over long-term follow-up, study finds | ACP Gastroenterology Monthly
The authors said their study shows long-term durability of weight loss after bariatric surgery with Roux-en-Y gastric bypass, as well as related improvements in type 2 diabetes, hypertension, and lipid levels.
Olmesartan may be associated with higher rate of enteropathy versus other ARBs | ACP Gastroenterology Monthly
The association appeared to be stronger among patients ages 65 years and older, those who were treated for more than a year, and those with higher cumulative olmesartan doses.
A 30-year-old woman is evaluated for a 2-month history of diarrhea with three to five loose stools per day.